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Background: Chemoradiation is the standard treatment for anal cancer. 3D conformal radiotherapy (3D-CRT) is
usually split in 2 sequences with a therapeutic break (gap) in between. Intensity-modulated radiation therapy (IMRT)
makes it possible to reduce treatment time by abandoning this gap. The purpose of this study was to compare
outcomes and toxicities in patients treated with either IMRT or 3D-CRT.
Methods: Between 2004 and 2011, the data of 51 patients treated with exclusive radiotherapy with or without
concomitant chemotherapy for non-metastatic anal carcinoma were retrospectively analyzed. Twenty-seven
patients were treated with 3D-CRT and 24 patients with IMRT, with a median dose delivered to the tumor of 59.4Gy
[30.6-66.6], whatever the radiotherapy technique (p= 0.99). The median follow-up was 40 months [26.4-51.6].
Results: There was no difference between the two groups for response to treatment (p= 0.46). Two-year overall
survival, locoregional relapse-free survival and colostomy-free survival rates were 88.5%, 63% and 60.3%, respectively
for the IMRT group and 81%, 76.5% and 81.1% for the 3D-CRT group (all NS). Ten patients (37%) in 3D-CRT and 11
patients (45.8%) in IMRT (p= 0.524) had grade 3 acute toxicity. No grade 4 toxicity occurred.
Conclusions: Our study suggests that further investigations concerning the use of IMRT to treat cancer of the anus
are warranted. IMRT makes it possible to remove the gap, but with no impact on the prognosis. Nonetheless, a
longer follow-up is essential to determine whether or not IMRT has an impact on late toxicity, local control and
survival compared with conventional 3D-CRT.
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Several randomized trials have shown that radioche-
motherapy with 5-Fluorouracil (5FU) and Mitomycin-C
(MMC) as the standard gave, at 4 years, an overall sur-
vival rate ranging from 60% to 72%, local control from
61% to 84% and colostomy-free survival of approxi-
mately 70% [1-3]. 3D conformal radiotherapy is usually
delivered with a therapeutic break (gap) between two* Correspondence: gcrehange@cgfl.fr
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reproduction in any medium, provided the orsequences. The EORTC (European Organization for Re-
search and Treatment of Cancer) 22953 phase II trial
showed that the duration of the gap between two
sequences could be reduced from 6 to 2 weeks by de-
creasing the prophylactic dose delivered to the lymph
nodes during the first sequence to 36 Gy [4]. The gap
provides a number of advantages. It allows healthy
tissues to regenerate and thus diminishes acute toxicity
and non-planned treatment interruptions. Nonetheless,
the gap could be detrimental for local control as it
allows tumor cells to proliferate. A post hoc analysis of
the RTOG (Radiation Therapy Oncology Group) 92-08
phase II trial retrospectively compared a cohort ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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At 8 years the rates of locoregional control (LRC),
colostomy-free survival (CFS) and overall survival (OS)
were better in the absence of a gap. In the literature, the
impact of treatment duration on survival and LRC
remains a matter of debate. Certain studies reported
that prolonged treatment with more frequent treat-
ment interruptions was associated with a poorer prog-
nosis [5-7]. In contrast, other studies showed no link
between the proportion of interruptions or total treat-
ment time and poor control or lower survival [8-10].
The acute toxicity of radiochemotherapy delivering a
dose around 55Gy is not negligible. The interest IMRT
lies in the need to reduce the dose to healthy organs
while maintaining the required dose to the target vol-
ume. IMRT may provide better protection of organs at
risk (OAR). The advantages of IMRT for other pelvic
sites are well known. There are, however, few data for
IMRT in the treatment of the anal cancer [6,11-14].
Dosimetric studies that compared IMRT with 3D-CRT
reported that IMRT provided better protection for
healthy tissues, and several retrospective clinical studies
reported that acute gastrointestinal and skin morbidity
was lower than that in the RTOG 9811 trial [6,11-15].
We hypothesized that with IMRT it would be possible
to permanently abandon the gap, maintain acceptable
levels of toxicity and improve local control. In this
attempt, we chose to abandon the gap rapidly after the
implementation of IMRT in our institution. The contro-
versial results of retrospective preliminary published
studies prompted us to retrospectively review the out-
comes and toxicities of anal cancer patients undergoing
exclusive 3D-CRT or exclusive IMRT with and without
a gap period at the Georges François Leclerc Cancer
Center (Burgundy, France) over the last decade.
Methods
Patients
The data for all the 51 patients treated with radiotherapy
with or without chemotherapy for non-metastatic anal
carcinoma in the Georges François Leclerc Cancer Cen-
ter (Burgundy, France) from 2004 to 2010 were analyzed
retrospectively. All of the patients had a thorough
examination before the treatment, including a clinical
examination, a thoracic-abdominal-pelvic CT-scan and
a biopsy. The characteristics of the patients and the
tumors are reported in Table 1.
Radiochemotherapy
Before the treatment, all patients had a simulation CT-
scan acquired in supine position. The first radiation
sequence delivered 30 to 45Gy, with 2 to 4 beams in
3D-CRT and 4 to 9 beams in IMRT. The second
sequence delivered a dose of up to 59.4Gy to a reducedvolume including the tumor and the invaded lymph
nodes, using 4 beams in 3D-CRT, and 4 to 9 beams in
IMRT. In the case of a unique sequence, median dose
delivered continuously and the technique used were
similar to that described above for the second sequence.
For all locally advanced tumors (T3, T4, and/or N+),
the first target volume concerned the tumor and the
full pelvis, including mesorectal nodes, bilateral inguinal
nodes, internal and external iliac lymph nodes. For
T1-T2 and N0 tumors, the first target volume concerned
the tumor and a smaller pelvic field which ruled out the
inguinal nodes. The delineation of the volumes and the
doses delivered during the first and the second sequence
of the radiotherapy were similar whatever the technique
used, 3D-CRT or IMRT. The second target volume con-
cerned the tumor and the initially-invaded lymph nodes.
In order to take into account interfraction and set-up
uncertainties, the margin applied around both target
volumes was 10 mm.
After 2008, all patients with anal carcinoma were trea-
ted with IMRT, whatever the target volume.
The treatment was planned on Eclipse software
(Varian Medical Systems, Palto Alto, CA). For the IMRT,
the priority was maximal coverage of the PTV, while the
secondary objective was to spare OAR (bladder, small
bowel (SB), femoral heads). Organs at risk were outlined
identically over time using the same policy in our insti-
tution. Genitals were not considered as a separate struc-
ture and no dose limits were applied. The SB was
defined as the abdominal cavity, thus including both the
small and large bowels and the visceral fat surrounding
the loops. The objectives of IMRT for the PTV were that
100% should receive at least 95% of the prescribed dose,
0% more than 107%, 50% more than the prescribed dose
and 50% less than the prescribed dose. The classical
dose-volume constraints for the IMRT planning were:
30% of the SB should receive <30 Gy, 50% of the bladder
should receive <50 Gy and the mean dose to the FH
should be <45 Gy. The IMRT plan was optimized to
minimize the proportion of both the PTV receiving
<95% and >107% of the prescribed dose. The isodose of
the prescription was 100%. Generally, the dose was nor-
malized to the mean dose planned in the target volume.
The schemes of concomitant chemotherapy were
those of the EORTC 22953 (5FU+MMC) or the EORTC
22011 study (CDDP+MMC) [16]. Figure 1 represents
the pelvic dose distribution using 3D-CRT vs. IMRT for
the same anal cancer patient and Figure 2 shows the
DVH comparison.Dosimetric analysis
This analysis was done on all the 38 patients who were
treated on the full pelvis, the 13 other patients were
Table 1 Characteristics of patients and tumors according to the type of treatment (3D-CRT versus IMRT)
3D-CRT (n= 27) IMRT (n= 24) Total (n= 51) p-value Chi2
Age Median 36.1 [40.7-92.2] 59.7 [49.8-88.1] 60.8 [40.7-92.2] 0.2575
Sex Male 8 (29.6%) 8 (33.3%) 16 (31.4%) 0.776
Female 19 (70.4%) 16 (66.7%) 35 (68.6%)
HIV No 8 (88.9%) 9 (100%) 17 (94.4%) 1
Yes 1 (11.1%) 1 (5.6%)
WHO 0 13 (54.2%) 18 (78.3%) 31 (66%) 0.233
1 8 (33.3%) 4 (17.4%) 12 (25.5%)
2 3 (12.5%) 1 (4.4%) 4 (8.5%)
T-stage T1/T2/Tis 12 (44.4%) 11 (47.8%) 23 (46%)
T3/T4 15 (55.6%) 12 (52.2%) 27 (54%) 0.811
Tx 0 1 (4.2%) 1 (2%)
N-stage N0 17 (65.4%) 10 (41.7%) 27 (54%) 0.093
N1/N2/N3 9 (34.6%) 14 (58.3%) 23 (46%)
Nx 1 (3.7%) 0 1 (2%)
Histology Squamous cell 23 (85.2%) 22 (91.7%) 45 (88.2%) 0.671
Others 4 (14.8%) 2 (8.3%) 6 (11.8%)
WHO: World Health Organization, HIV: Human immunodeficiency virus.
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spectively collected. For the FH, the mean dose was
recorded. For the SB, the mean dose (Dmean), the
maximal dose (Dmax), as well as the volume receiving
30 Gy (V30), V40, V50 and V60 were studied. For the
bladder, Dmean, Dmax and the minimal dose (Dmin) as
well as the dose delivered to 95% of the bladder (D95)
were analyzed. The Dmax, Dmin, Dmean and D95 to
PTV1 and PTV2 were analyzed.
Gap
For locally advanced tumors treated with 3D conformal
concomitant chemoradiotherapy, a 2-week gap was
planned according to the EORTC 22953 trial. In 2008,
with the introduction of IMRT, the gap was quickly
abandoned in routine practice.
Toxicity
During radiotherapy, patients had a consultation at least
once a week, during which toxicity were prospectively
recorded and graded according to the CTCAE v.3.0.
Toxicity that became apparent 6 months after the treat-
ment was considered late.
Evaluation of the response and follow-up
A complete response (CR) was defined as the absence of
any residual tumor, partial response (PR) as the persist-
ence of a lesion after a response of more than 30%, and
stable disease (SD) as a response to the treatment of
less than 30%. After the treatment, the patients were
seen every 3 months for one year, and then once every4 months for 3 years. In cases of remission, the patients
were seen every 6 months thereafter. A digital rectal
examination and anuscopy were performed. Biopsy or
imaging examinations were conducted only when there
were signs. Local recurrence was defined as the appear-
ance of a clinical macroscopic lesion, whether or not it
was proven histologically from a biopsy, at the site of the
initial disease.
Statistics
The median follow-up was calculated using the Reverse
Kaplan-Meier method. The Kaplan Meier method
was used to determine OS, Loco-regional Relapse-Free
Survival (LRFS), Disease-Free Survival (DFS) and CFS.
These survivals were calculated from the date of diag-
nosis to the event, to death or to the date of the last
news. The survival curves were compared using the
Log Rank test. Uni- and multivariate analyses were
done using the Cox model. The statistical analysis was
done using STATA V11 (STATA Corp, College Station,
TX) software.
Results
Of the 51 patients, 27 were treated with 3D-CRT and
24 with IMRT. Analysis of the 2 groups revealed no
significant differences for the characteristics of either
the patients or the tumors (Table 1).
Radiotherapy
In 38 patients (74.5%) the full pelvis was irradiated with
2 to 4 fields in 3D-CRT, and 4 to 9 fields in IMRT. The
Figure 1 Comparison of dose distribution on planning CT with 3D-CRT and IMRT for a same patient with a locally advanced T3N+
anal cancer. Legend: The isodose distribution shows up in colorwash with the 95% isodose line selected Left column (A.) axial CT slice using
3D-CRT technique with small coronal and sagittal views above; Right column (B.) axial CT slice using IMRT technique. with small coronal and
sagittal views above.
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well balanced, 18 treated with 3D-CRT and 20 with
IMRT (p=0.173). Twenty-two had a gap during the treat-
ment, and 16 did not have a programmed break.
The median dose delivered to the CTV1 was 36Gy
[30.0-45.0], with no difference for the technique ([30.6-45]
for IMRT and [30-45] for 3D-CRT). The median dose
delivered to the CTV2 was 59.4Gy [30.6-66.6], with no
difference for the technique ([30.6-65] for IMRT and
[32.4-66.6] for 3D-CRT). Forty-nine patients (96%)
received the totality of the initially-planned treatment.Chemotherapy
Forty-one patients (80.4%) had concomitant chemother-
apy: capecitabine alone (1), MMC combined with 5FU
or capecitabine (36), MMC and CDDP (4). Nineteen
were treated with 3D-CRT and 22 with IMRT. Twenty-
two had a gap during the treatment, and 19 did not have
a programmed break.
For the 10 patients not treated with chemotherapy, the
reason was the tumor stage (T1-T2 and N0), the age
(over 80 years old) or a refusal. The patients receivingchemotherapy or not were equally divided between 3D-
CRT versus IMRT, p= 0.081.
Duration of treatment and interruptions
Median duration of the treatment was 56 days [22-103]
(59 versus 47 days with 3D-CRT and IMRT respectively,
p= 0.0007). A gap was planned in 29 patients (57%),
23 with 3D-CRT and 6 with IMRT (p< 0.0001). Treat-
ment was stopped for toxicity in 9 patients (17.6%),
4 with 3D-CRT and 5 with IMRT (p= 0.48).
Toxicity
Acute and late toxicity is presented in Table 2.
Two patients stopped definitively the treatment
around 30Gy because of toxicity (rectovaginal fistula and
G3 perineal skin toxicity). Ten patients (37%) in 3D-
CRT and 11 (45.8%) in IMRT, (p= 0.524) presented G3
acute hematological and non-hematological toxicity.
There were no cases of G4 toxicity. One patient in the
3D-CRT group and 5 in the IMRT group developed G3
acute digestive toxicity (p= 0.088). Concerning the G3
perineal skin toxicity, there were 9 cases in the 3D-CRT
Figure 2 Dose Volume Histogram (DVH) comparison of 3D-CRT vs. IMRT for the same anal cancer patient.
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3D-CRT group and none in the IMRT group had G3 late
toxicity (p= 0.491).
Clinical response
Forty-nine patients (96.1%) were examined during the 3
months following the end of the treatment. Thirty-nine
patients (79.6%) had CR, 9 (18.3%) PR and 1 (2%) dis-
ease progression. There was no difference between the 2
groups for response to treatment (p= 0.46).
Follow-up and outcomes
The median follow-up for the whole cohort was
40 months [26.4-51.6], 60 months [45.6-69.6] for 3D-Table 2 Acute and late toxicity
G1/G2
3D-CRT n=27 IMRT n=24 Total n=51
Acute Perineal skin 13 (48.1%) 13 (54.2%) 26 (51%)
Diarrhea 12 (0.44%) 11 (45.8%) 23 (45.2%)
Pain 10 (37%) 15 (62.5%) 25 (49%)
Neutropenia 1 (0.04%) 0 1 (2%)
Late Rectal bleeding 6 (22.2%) 6 (0.25%) 12 (24.5%)
Impotence 0 0 0CRT and 23 months [15.6-38.4] for IMRT. At the time
of the analysis, 34 patients (66.6%) were still alive: 33
were alive without disease, and 1 in the IMRT group
presented a locoregional and metastatic recurrence.
Median OS was 5.1 years. The OS rate at 2 years was
84.9% (81.1% 3D-CRT versus 88.5% IMRT, p= 0.58).
LRFS rate at 2 years was 71.5% (76.5% 3D-CRT versus
63% IMRT, p= 0.43). CFS rate at 2 years was 73.6%
(81.1% 3D-CRT versus 60.3% IMRT, p= 0.12).
Seven patients (13.7%) developed local recurrence,
4 with IMRT and 3 with 3D-CRT. Three patients
underwent abdominoperineal resection (APR) and one
patient had R0 conservative surgery. Four patients
(7.8%) developed recurrence in the lymph nodes, 3 withG3/G4
P value 3D-CRT n=27 IMRT n=24 Total n=51 P value
0.756 9 (33.3%) 9 (37.5%) 18 (35.3%) 0.756
1 1 (3.7%) 1 (4.2%) 2 (3.9%) 1
0.331 1 (3.7%) 3 (12.5%) 4 (7.8%) 0.331
1 1 (3.7%) 1 (4.2%) 2 (3.9%) 1
1 1 (3.9%) 0 1 1
1 1 (12.5%) 0 1 1
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1 with 3D-CRT.
Dosimetric comparison of 3D-CRT and IMRT
The results of the analysis for PTV1 and 2 as well as
for the organs at risk, depending on the radiotherapy
technique used (3D-CRT versus IMRT), are presented
in Table 3.
3D-CRT was compared with IMRT for the whole
population as well as for patients with radiation to the
pelvis. For the FH and the SB, there was no significant
difference between the groups, even for the pelvis sub-
groups. For the bladder, there was no difference between
the two groups for the whole population. However, forTable 3 Dosimetric analysis in the group of patients with






Total dose 58.3 Gy 58.9 Gy 0.366
Urinary bladder
D mean 44.8 Gy 34.5 Gy 0.008
Dmax 59.8 Gy 55.4 Gy 0.363
Dmin 32.5 Gy 19.0 Gy 0.034
D95 34.1 Gy 22.8 Gy 0.061
Right femoral
head Dmean 29.9 Gy 26.9 Gy 0.582
Left femoral head
Dmean 32.8 Gy 27.1 Gy 0.133
Small bowel
Dmean 13.4 Gy 17.8% 0.632
Dmax 47.8 Gy 46.3% 1
V30 16% 22.7% 0.719
V40 0% 8.5% 0.195
V50 0% 2.9% 0.273
V60 0% 0.5% 0.484
PTV1
Dmax 62.1 Gy 62.3 Gy 0.473
Dmin 26.6 Gy 27.2 Gy 0.702
Dmean 51.1 Gy 50.3 Gy 0.962
D95 37.2 Gy 37.4 Gy 0.702
PTV2
Dmax 62.2 Gy 62.3 Gy 0.426
Dmin 33.9 Gy 44.8 Gy 0.408
Dmean 59.9 Gy 58.8 Gy 0.655
D95 57.8 Gy 57.6 Gy 0.014
V30: volume of the considered organ receiving 30Gy or less (in %); V40:
volume of the considered organ receiving 40Gy or less (in %); V50: volume
of the considered organ receiving 50Gy or less (in %); V60: volume of the
considered organ receiving 60Gy or less (in %); Dmax: maximal dose; Dmin:
minimal dose; Dmean: mean dose; D95: dose delivered to 95% of the target.the sub-group with treatment to the pelvis, the mean
dose delivered to the bladder was 44.8Gy in 3D-CRT
and 34.5Gy in IMRT (p< 0.007).
For PTV1 and 2, there was no significant difference
between the 2 groups for the Dmax, Dmin, Dmean,
and D95.
Predictive factors for local control, and overall and
colostomy-free survival
The factors tested in univariate analysis are reported in
Table 4. In multivariate analysis, no factor had a signifi-
cant impact on OS and DFS. With regard to LRFS,
only N stage was statistically associated in multivariate
analysis (p= 0.035). In multivariate analysis, only the
WHO (World Health Organization) score had a signifi-
cant impact on CFS (p= 0.032).
Predictive factors for G3 or G4 acute toxicity
No factors were associated with the appearance of G3+
toxicity, neither in uni- nor in multivariate analysis. In
particular, the radiotherapy technique had no impact.
Discussion
Studies involving series of patients treated with radioche-
motherapy, associating 2D radiotherapy with 5FU and
MMC, reported rates of LRC at 4 years (4y) ranging from
61% to 84% [1-3,15]. Studies that used IMRT reported
rates of LRC from 83.9% to 91.9% (3y) [6,12-14,17-20].
In the study of Bazan et al. LRC with IMRT was signifi-
cantly greater than that with 3D non conformal RT (3y,
92% versus 57%, p< 0.01) [6]. In our study, LRC at 2 years
was 65.8% in IMRT versus 88% in 3D-CRT (p= 0.21).
With IMRT, we found 12.5% of lymph nodes recurrences
in a population of whom 58.3% were node positive (N+).
This finding is in keeping with published data for IMRT
[12,20]. We found in multivariate analyses, that the tech-
nique used was not a predictor of LRFS. Nevertheless,
it remains difficult to compare IMRT results across insti-
tutions because of technical differences and learning
curves needed with IMRT. The quality assurance of
radiotherapy is often lacking in such studies and should
be mandatory in the future when delivering IMRT.
OS from 58% to 75% (5y) has been reported in series
of patients undergoing 2D-based radiochemotherapy [1-
3,15]. In the majority of studies on IMRT, OS ranged
from 63% to 94% (2y). Bazan et al. reported significantly
greater OS in patients treated with IMRT than in those
treated with 3D non-conformal RT (3y, 88% versus
52%, p< 0.01) [6]. In our study, 2y-OS was 81.1% in the
3D-CRT and 88.5% in the IMRT group (p= 0.58).
CFS of around 70% at 4y with 2D radiochemotherapy
has been reported in the literature [1-3,15]. Data for
patients treated with IMRT showed 3y-CFS from 82% to
91%. In our study, 2y-CFS was 81.1% in the 3D-CRT and
Table 4 Predictors of local control, overall and colostomy-free survival in univariate analysis (n= 51)
Overall survival Locoregional relapse-free survival Colostomy-free survival
HR CI 95% p-value HR CI 95% p-value HR CI 95% p-value
WHO
0 1 [0.99-7.17] 0.053 1 [0.83-5.64] 0.115 1 [1.3-8.07] 0.012
1/2 2.66 2.16 3.24
T Stage
T1/T2/in situ 1 [0.45-3.42] 0.684 1 [0.38-2.64] 1 1 [0.44-2.73] 0.846
T3/T4 1.23 1 1.1
N Stage
N0 1 [0.95-7.5] 0.062 1 [0.97-7.46] 0.057 1 [1.04-6.91] 0.042
N1/N2/N3 2.67 2.69 2.68
Histology
Squamous cell cancer other 1 0.86 [0.2-3.82] 0.846 1 0.83 [0.19-3.65] 0.809 1 0.68 [0.16-2.97] 0.612
Treatment duration
<56 days 1 [0.26-1.96] 0.511 1 [0.23-1.60] 0.317 1 [0.23-1.49] 0.262
>56 days 0.71 0.61 0.59
Total dose
<50 Gy 1 [0.11-6.47] 0.874 1 [0.14-8.09] 0.951 1 [0.04-0.88] 0.033
>50 Gy 0.85 1.07 0.19
Technique
3D-CRT 1 [0.46-3.94] 0.580 1 [0.55-3.98] 0.431 1 [0.81-5.66] 0.125
IMRT 1.35 1.48 2.14
Treatment breaks for toxicity
Yes 1 [0.23-4.46] 0.996 1 [0.37-4.56] 0.680 1 [0.16-2.96] 0.607
No 1 1.3 0.68
Planned gap
Yes 1 [0.29-3.17] 0.943 1 [0.3-2.4] 0.765 1 [0.37-3.17] 0.882
No 0.96 0.85 1.08
Pelvic radiotherapy
Yes 1 [0.34-3.33] 0.905 1 [0.44-5.35] 0.501 1 [0.45-4.1] 0.587
No 1.07 1.54 1.36
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of whom were in the IMRT group, had a colostomy
for rectovaginal fistula (1), local recurrence (2), and for
comfort in a context of incontinence (2).
Several studies explored the benefits of IMRT with
regard to reducing adverse effects (Table 5). For Bazan
et al. G3+ non-hematological toxicity were significantly
more frequent in the 3D-RT group (65% versus 21%,
p= 0.003) [6]. In multivariate analysis, the risk of devel-
oping G3+ toxicity was significantly lower with IMRT
than with 3D-RT. The incidence of G3+ acute skin tox-
icity with 2D-RT was 48% in the 5FU+MMC arm of the
RTOG 98-11 trial, and 17% in the UKCCCR trial [1,15].
Studies that used IMRT reported skin toxicity ranging
from 0 to 38% [6,12-14,17,20]. G3 acute toxicity was
significantly less frequent with IMRT than with 3D-RT(21% versus 41%) [6]. In our cohort, we recorded 35.3%
of G3 skin toxicity, and no G4 toxicity (33.3% 3D-CRT
versus 37.5% IMRT, p= 0.756). With 2D-radioche-
motherapy, acute G3+ gastrointestinal toxicity was 35%
for Ajani et al. and 5% in the UKCCCR trial [1,15].
With IMRT the rate of G3+ acute digestive toxicity ran-
ged from 0 to 66%. Bazan et al. reported 29% and 7%
of G3+ acute digestive toxicity in 3D-RT compared
with IMRT [6]. We found 6 (11.8%) G3 acute digestive
toxicity (including anitis and diarrhea) in the 51 patients,
5/24 with IMRT (20.8%) and 1/27 (3.7%) with 3D-CRT
(p= 0.088), and no G4 toxicity. In contrast to published
studies that compared 3D non conformal RT with IMRT,
2 AP-PA beams were used most often. We believe our
3D technique was more conformal by delivering 2 to
4 fields. This difference in dose distribution may explain







Treatment breaks (%) Breaks (days) Rates of grade 3+
GI toxicity (%)
Rates of grade 3+
skin toxicity (%)




Pepek et al. [13] 47 Median 14 90 (2-y) 18 (AT) Median 5 (2-7) 10 0 24 CTC V3
Bazan et al. [6] 46 Median CTC V3
17 (3D) 3D : 26 3D : 56.7 (3-y) 3D : 88 (AT) 3D : 12 3D : 29 3D : 41 3D : 29
29(IMRT IMRT: 32 IMRT : 91.9 (3-y)
(P<0.01)
IMRT : 34.5 (90% AT, 10% NC)
(P=0.001)
IMRT : 1.5 (P<0.0001) IMRT: 7 IMRT: 21 IMRT : 21
Salama et al. [14] 53 Median 83.9 (1.5-y) 41.5 Median 15 38 59 CTC V3
14.5 (AT) 4 (2-14)
RTOG 0529. [19] 43 24 95 (2-y) 40 Median 7 10 61 CTC V3
(AT+NC) 35 (toxicity) 2 (2-24)
Kachnic et al. [20] 52 23.2 80 (2-y) NR NR 22 20 NR CTC V3
Milano et al. [12] 17 20.3 82 (2-y) 24 (AT) NR 0 0 38 RTOG
Hodges et al. [17] 6 25 100 (3-y) 50 1- 3 67 0 CTC V3
Vautravers-Dewas et al. 51 Median 17.6 Median 3D : 3.7 35.3 4 CTC V3
3D : 60 88 (2-y) (AT) 15 (1-43) IMRT : 20.8
IMRT : 23 65.8 (2-y) (P=0.088)
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concerning the low toxicity in 3D-CRT group.
Retrospective studies have confirmed the need for
non-programmed treatment breaks notably because of
skin or digestive reactions. Ajani et al. reported a rate of
breaks of 61% with 2D-chemoradiation [15]. With IMRT,
the number of breaks for toxicity ranged from 18% to
50%. For Bazan et al. IMRT made it possible to signifi-
cantly reduce the median duration of the treatment
(57 versus 40 days, p< 0.0001) [6]. Breaks for toxicity
were significantly more frequent with 3D-RT than with
IMRT (88% versus 34.5%, p= 0.001). In our study,
we found 11.1% and 20.8% of breaks for toxicity for 3D-
CRT and IMRT, respectively (p= 0.48). Our rate of
breaks with IMRT was comparable to Bazan et al.
(20.8% versus 24.1%) [6]. However, we found far fewer
breaks with 3D-CRT (11.1% versus 88%), which very
probably explains the discordance of the results with
regard to the impact of the technique used.
With IMRT it is possible to reduce total treatment
time: median treatment time was 49 and 42 days in
the RTOG 98-11 trial (3D) and the 0529 trial (IMRT),
respectively [18]. Certain studies reported that prolonged
treatment and more frequent treatment breaks were
associated with a poorer prognosis [5,7]. In the series by
Bazan et al. the patients who did not interrupt treatment
had better OS, LRC and PFS at 3 years than those who
had breaks (respectively 90% versus 45% p= 0.03, 95%
versus 67% p= 0.02, 89% versus 63% p= 0.04) [6]. In con-
trast, other studies showed no association between the
percentage of breaks and total treatment time, and poor
control or diminished survival [9,10]. Although Ben
Joseph et al. found in a post hoc analysis of RTOG trials
that overall treatment time was a significant predictor
for local failure (but not overall survival), radiation dose,
radiation duration and radiation intensity showed no
correlation with colostomy failure or local failure rates
in multivariate analysis [8]. Because patients in the
experimental arm of RTOG 98-11 had significantly
longer overall treatment time (4 courses of neoadjuvant
5-FU+Cisplatin), an additional analysis considering only
patients treated with concomitant 5-FU + MMC but
without neoadjuvant chemotherapy (i.e. mean overall
treatment time of 45 days) showed no correlation but a
trend (p= 0.078) between the duration of radiotherapy
and the colostomy failure rate. In our study, we found
no significant association between numbers of breaks,
duration of the treatment, existence of a planned gap
and prognosis for either LRC or survival.
Nonetheless, our analysis does include a number of
limitations linked to the retrospective nature of the data
collection, as a result of which the doses of radiation
and the chemotherapy protocols were heterogeneous.
Even though our median follow-up in the group ofpatients treated with IMRT was short, our results are
comparable to those in series with a similar follow-up
[13,14]. Our results suggest that the clinical benefit of
IMRT is limited to the reduction in treatment time, and
they must be considered with caution together with the
preliminary data already published. We are now awaiting
the results of the RTOG 0529 phase II trial, with a
longer follow-up, to provide a definitive answer concern-
ing the benefits of IMRT. A phase III trial to compare
IMRT with 3D-CRT is required given the different
results in the literature to conclusively address this issue.
Quality of life using the two protocols also needs to
be evaluated.
Conclusion
Our study, even though it suffers from the classical lim-
itations of a retrospective analysis, suggests that further
investigations concerning the use of IMRT as a standard
to treat anal cancer are necessary. IMRT makes it pos-
sible to reduce treatment time, notably by abandoning
the gap, but with no impact on the prognosis. Nonethe-
less, a longer follow-up is essential to determine whether
or not IMRT has an impact on late toxicity, local control
and survival compared with conventional 3D-CRT.
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